2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

SH-SY5Y human neuroblastoma cells

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

2

Fluorescent Dyes

2

Biochemical Assay Reagents

1

Inhibitory Antibodies

4

Natural
Products

1

Isotope-Labeled Compounds

1

Click Chemistry

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0303
    Idebenone
    5+ Cited Publications

    		 Mitochondrial Metabolism Apoptosis Neurological Disease
    Idebenone, a well-appreciated mitochondrial protectant, exhibits protective efficacy against neurotoxicity and can be used for the research of Alzheimer's disease, Huntington's disease. Idebenone (oxidised form) has a dose-dependent inhibitory effect on the enzymatic metabolism of arachidonic acid in astroglial homogenates (IC50=16.65 μM) . Idebenone, a coenzyme Q10 analog and an antioxidant, induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells . Idebenone quickly crosses the blood-brain barrier.
    Idebenone
  • HY-W143216
    Azure C

    Monomethylthionine

    		 Amyloid-β Tau Protein HSP Neurological Disease
    Azure C (Monomethylthionine) acts as a tau oligomer inhibitor and Aβ42 oligomerization inhibitor. Azure C regulates hsp70 ATPase activity, thereby mediating the clearance of tau protein. Azure C reduces the levels of toxic tau oligomers by promoting the formation of non-toxic tau aggregates, rescues neuroblastoma cells from tau oligomer-induced toxicity, and binds to and inhibits Aβ42 oligomerization. Azure C is generated via continuous oxidation of methylene blue or azure B through a horseradish peroxidase-mediated reaction. Azure C can be used in research related to tauopathies, including Alzheimer's disease .
    Azure C
  • HY-N6013
    Aloin (mixture of A&B)

    		MMP Proteasome Keap1-Nrf2 TGF-beta/Smad Interleukin Related SOD Bacterial Fungal Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Aloin (mixture of A&B) is an orally active anthraquinone derivative isolated from Aloe vera. Aloin (mixture of A&B) mitigates airway impairment and exerts neuroprotective, anti-inflammatory, antioxidant, antibacterial, antifungal, antiviral and antitumor effects. Aloin (mixture of A&B) inhibits Clostridium histolyticum collagenase, granulocyte matrix metalloproteinases and human 20S proteasome. Aloin (mixture of A&B) upregulates the Nrf2/HO-1 pathway, suppresses the TGF-β/Smad2/3 pathway. Aloin (mixture of A&B) reduces IL-4/IL-5/IL-13 levels, and reverses oxidative stress markers (MDA, SOD, GSH). Aloin (mixture of A&B) can be used for research on chronic ulcers, burns, wounds, inflammatory and degenerative disorders, asthma and neuroblastoma .
    Aloin (mixture of A&B)
  • HY-B0512
    Sulfamerazine
    4 Publications Verification

    RP2632

    		 Antibiotic Bacterial α-synuclein Infection Neurological Disease
    Sulfamerazine (RP2632) is a brain-penetrant and orally active sulfonamide antibiotic and α-synuclein inhibitor with human α-synuclein KD of 352 μM. Sulfamerazine inhibits the synthesis of dihydrofolate by bacteria, thereby inhibiting bacterial growth. Sulfamerazine inhibits α-synuclein fibrillation, reduces α-synuclein aggregation-associated toxicity and α-synuclein aggregate accumulation. Sulfamerazine can be used for the research of Parkinson’s disease and bacterial infection .
    Sulfamerazine
  • HY-136832
    Noribogaine hydrochloride

    		Serotonin Transporter Potassium Channel Arrestin Opioid Receptor Cardiovascular Disease Neurological Disease
    Noribogaine hydrochloride is an orally active, blood-brain barrier permeable SERT inhibitor (IC50=50-300 nM) and hERG channel blocker. Noribogaine hydrochloride enhances serotonergic transmission, activates the κ-opioid receptor (OPRK) G protein signaling pathway and inhibits β-arrestin recruitment. Meanwhile, Noribogaine hydrochloride blocks the μ-opioid receptor (OPRM) signaling pathway as well as ion channels associated with cardiac repolarization. Noribogaine hydrochloride induces neuritogenesis, upregulates GDNF mRNA expression, and modulates opioid tolerance. Noribogaine hydrochloride reduces alcohol-seeking behavior in experimental animals, and is widely used in studies related to depression, addiction, alcoholism, and cardiotoxicity .
    Noribogaine hydrochloride
  • HY-N0046
    Notoginsenoside Fe

    Notoginseng triterpenes; Ginsenoside Mb

    		 Apoptosis Src Neurological Disease Metabolic Disease Cancer
    Notoginsenoside Fe (Notoginseng triterpenes; Ginsenoside Mb) is a saponin with anti-obesity and anti-neuroblastoma activities. Notoginsenoside Fe can be isolated from leaves of Panax notoginseng. Notoginsenoside Fe specifically activates paraventricular nucleus neurons in the hypothalamus, effectively reducing body weight, improving fasting blood glucose and protecting liver function by decreasing food intake, increasing resting metabolic rate and enhancing energy expenditure. Notoginsenoside Fe also inhibits the c-Src signaling pathway, blocks the proliferation and viability of human neuroblastoma cells, while improving mitochondrial dysfunction and alleviating apoptosis. Notoginsenoside Fe can be used in studies related to diet-induced obesity and neuroblastoma .
    Notoginsenoside Fe
  • HY-119435
    Triallate

    		Herbicide Environmental Pollutants Others
    Triallate is a selective thiocarbamate herbicide. Triallate regulates the biosynthesis of very-long-chain fatty acids and inhibits the elongation and division of plant cells. Triallate is used to control wild oats in barley, spring wheat, durum wheat, winter wheat and sugar beets .
    Triallate
  • HY-119357
    TN-16

    		Microtubule/Tubulin Apoptosis Autophagy Neurological Disease Cancer
    TN-16 is a Microtubule polymerization inhibitor. TN-16 induces G2/M cell cycle arrest, metaphase mitotic arrest and Apoptotic cell death in cells, and blocks late Autophagic flux by inhibiting autophagosome-lysosome fusion. TN-16 suppresses tumor growth in syngeneic mouse breast cancer models. TN-16 can be used in research related to neuroblastoma, cervical cancer, breast cancer and other tumors .
    TN-16
  • HY-N0143A
    Phlorizin dihydrate
    10+ Cited Publications

    Floridzin dihydrate

    		 SGLT PI3K Akt GLUT NF-κB JAK STAT Caspase Apoptosis DNA/RNA Synthesis mTOR Bacterial Infection Neurological Disease Metabolic Disease Cancer
    Phlorizin (Floridzin) dihydrate is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC50 of 0.04 μM and a Ki of 39 nM against hSGLT2, and an IC50 of 0.17 μM and a Ki of 0.31 μM against hSGLT1. Phlorizin dihydrate promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin dihydrate reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin dihydrate induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin dihydrate also exhibits antibacterial, anti-inflammatory and neuroprotective activities .
    Phlorizin dihydrate
  • HY-172705
    DSPE-PEG2000-RVG29

    		Liposome nAChR Neurological Disease
    DSPE-PEG2000-RVG29 is a PEG conjugate composed of DSPE and rabies virus glycoprotein 29 (RVG29). RVG29 specifically binds to nicotinic acetylcholine receptors (nAChR) at the blood-brain barrier (BBB), crosses the BBB, and mediates receptor-dependent transcytosis. DSPE-PEG2000-RVG29 can be used for brain-targeted drug delivery, surface modification of nanocarriers, as well as gene and nucleic acid delivery. DSPE-PEG2000-RVG29 is applicable to research related to hypoxic-ischemic brain injury, Parkinson's disease, and other conditions .
    DSPE-PEG2000-RVG29
  • HY-179177
    AO-365/43472821

    		DYRK CDK Tau Protein Amyloid-β Neurological Disease
    AO-365/43472821 is a selective, brain-penetrant Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitor (IC50 = 0.29 μM) and shows a significant inhibitory effect on (CDC-like kinase 1) CLK1 (IC50 = 0.08 μM). AO-365/43472821 could protect the human neuroblastoma cell line SH-SY5Y from Okadaic acid (HY-N6785) (OA)-induced injury. AO-365/43472821 decreased tau (pSer396)/tau and Aβ1-42 protein expression. AO-365/43472821 can be used for the study of Alzheimer's disease .
    AO-365/43472821
  • HY-W777283
    Idebenone-13C,d3

    		Isotope-Labeled Compounds Apoptosis Mitochondrial Metabolism Neurological Disease
    Idebenone- 13C,d3 is the deuterium labeled and 13C-labeled Idebenone (HY-N0303). Idebenone, a well-appreciated mitochondrial protectant, exhibits protective efficacy against neurotoxicity and can be used for the research of Alzheimer's disease, Huntington's disease. Idebenone (oxidised form) has a dose-dependent inhibitory effect on the enzymatic metabolism of arachidonic acid in astroglial homogenates (IC50=16.65 μM) . Idebenone, a coenzyme Q10 analog and an antioxidant, induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells . Idebenone quickly crosses the blood-brain barrier.
    Idebenone-13C,d3
  • HY-178997
    NFE2L1 activator-1

    		Ferroptosis Glutathione Peroxidase Cancer
    NFE2L1 activator-1 (Compound 5b) is a potent nuclear factor erythroid 2-related factor 1 (NFE2L1) activator (EC50 = 2.4 µM). NFE2L1 activator-1 effectively resists ferroptosis (Ferroptosis). NFE2L1 activator-1 can specifically activate the NFE2L1 signaling pathway to upregulate GPX4, PSMB7, PSMC4. NFE2L1 activator-1 can be used in cancer research .
    NFE2L1 activator-1
  • HY-161156
    BChE-IN-26

    		Cholinesterase (ChE) Neurological Disease Cancer
    BChE-IN-26 (Compound 7b) is a selective AChE and BChE inhibitor with Ki value of 35 μM and 1.6 μM. BChE-IN-26 has cytotoxicity to human neuroblastoma (SH-SY5Y) cell line. BChE-IN-26 can be used for the research of Alzheimer’s disease .
    BChE-IN-26
  • HY-N0303R
    Idebenone (Standard)

    		Reference Standards Mitochondrial Metabolism Apoptosis Neurological Disease
    Idebenone (Standard) is the analytical standard of Idebenone. This product is intended for research and analytical applications. Idebenone, a well-appreciated mitochondrial protectant, exhibits protective efficacy against neurotoxicity and can be used for the research of Alzheimer's disease, Huntington's disease. Idebenone (oxidised form) has a dose-dependent inhibitory effect on the enzymatic metabolism of arachidonic acid in astroglial homogenates (IC50=16.65 μM) . Idebenone, a coenzyme Q10 analog and an antioxidant, induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells . Idebenone quickly crosses the blood-brain barrier.
    Idebenone (Standard)
  • HY-162860
    FO-4-15

    		mGluR CaMK Tau Protein Neurological Disease
    FO-4-15 is an mGluR1/CaMKIIα activator. FO-4-15 has a protective effect against H2O2 in human neuroblastoma (SH-SY5Y) cells. FO-4-15 can improve cognitive impairment in Alzheimer’s disease mice by activating the mGluR1/CaMKIIα pathway, and can reduce Aβ accumulation, hyperphosphorylated Tau, and synaptic damage .
    FO-4-15
  • HY-172544
    TTBK1/2-IN-3

    		Tau Protein Neurological Disease
    TTBK1/2-IN-3 (Compound 10) is a potent inhibitor of tau tubulin kinase 1 (TTBK1) and TTBK2, with IC50 values of 579 nM and 258 nM, respectively. TTBK1/2-IN-3 inhibits the phosphorylation of TDP-43. TTBK1/2-IN-3 reduces the expression of primary cilia on the surface of iPSCs .
    TTBK1/2-IN-3
  • HY-118041
    PMPMEase-IN-1

    		Carboxylesterase (CES) Endogenous Metabolite Cancer
    PMPMEase-IN-1 is an allylated methylated protein methylesterase inhibitor with the property of inhibiting PMPMEase activity. PMPMEase-IN-1 may provide a useful strategy for cancer inhibition by enhancing its affinity for polyisoprenyl derivatives. PMPMEase-IN-1 showed the potential to have an effective concentration (EC50) value in causing degeneration of human neuroblastoma SH-SY5Y cells. Specific inhibition of PMPMEase-IN-1 may help regulate the metabolism of polyisoprenyl proteins and thus maintain normal cell survival. Further development and application of PMPMEase-IN-1 may open up new avenues for inhibiting degenerative diseases and cancer .
    PMPMEase-IN-1
  • HY-119399
    Salithion

    Dioxabenzofos

    		 Cholinesterase (ChE) Neurological Disease
    Salithion is an acetylcholinesterase inhibitor and neurotoxicant. Salithion binds to the active site of acetylcholinesterase to interfere with acetylcholine hydrolysis, and there is an enantioselective difference between its (R) and (S) enantiomers .
    Salithion
  • HY-184159
    AChE/BChE/MAO-A-IN-2

    		Cholinesterase (ChE) Monoamine Oxidase Neurological Disease Cancer
    AChE/BChE/MAO-A-IN-2 is an AChE, BChE, and MAO-A inhibitor with IC50 values of 104.28 nM, 23.04 nM, and 215.50 nM, respectively. AChE/BChE/MAO-A-IN-2 exhibits selective antiproliferative activity against cancer cells and low toxicity toward normal cells. AChE/BChE/MAO-A-IN-2 can be used for the research of alzheimer's disease, neuroblastoma .
    AChE/BChE/MAO-A-IN-2
  • HY-183798
    BChE/MAO-B-IN-6

    		Cholinesterase (ChE) Monoamine Oxidase Interleukin Related Neurological Disease
    BChE/MAO-B-IN-6 is a dual inhibitor with inhibitory activity against both butyrylcholinesterase (BChE) and monoamine oxidase B (MAO B), with an IC50 of 557 nM against BChE and an IC50 of 142 nM against MAO B. BChE/MAO-B-IN-6 reduces IL-6 release from stimulated microglia and antagonizes 6-hydroxydopamine (HY-B1081) toxicity in neuroblastoma cells. BChE/MAO-B-IN-6 can be used in the research of neurodegenerative diseases .
    BChE/MAO-B-IN-6
  • HY-181268
    MAO-B-IN-53

    		Monoamine Oxidase Neurological Disease
    MAO-B-IN-53 is a human monoamine oxidase B (hMAO-B) inhibitor with an IC50 of 0.066 μM. MAO-B-IN-53 exhibits mixed reversible inhibition, binds stably to the hMAO-B active site, and shows high selectivity over hMAO-A. MAO-B-IN-53 acts as a neuroprotective agent, protects against 6-OHDA-induced damage, and exhibits low neurotoxicity in neuroblastoma cells. MAO-B-IN-53 can be used for the research of Parkinson's disease .
    MAO-B-IN-53
  • HY-N17468
    Neocrocin B

    		Neurological Disease
    Neocrocin B is a carotenoid crocin. Neocrocin B inhibits L-Glutamic acid (HY-14608)-induced neuronal cell damage in a dose-dependent manner. Neocrocin B can be used in studies related to neuronal injury .
    Neocrocin B
  • HY-182380
    ODZ10117

    		STAT NOD-like Receptor (NLR) Apoptosis Others Neurological Disease Inflammation/Immunology Cancer
    ODZ10117 is a STAT3 and NLRP3 inhibitor with a human STAT3 SH2 domain IC50 of 7.5 μM. ODZ10117 binds to the STAT3 SH2 domain, suppressing tyrosine phosphorylation, dimerization, nuclear translocation, and transcriptional activity. ODZ10117 binds to NLRP3, impairs NEK7 interaction, prevents inflammasome formation, and inhibits caspase-1 and IL-1β cleavage.ODZ10117 reduces MSU (HY-B2130A)-induced IL-1β release, lowers LPS (HY-D1056)-induced sepsis mortality, and exhibits anti-inflammatory effects. ODZ10117 induces apoptosis, suppresses breast cancer cell migration and invasion, reduces tumor growth and lung metastasis, and extends survival in breast cancer models. ODZ10117 can be used for the research of Monosodium urate (HY-B2130A)-induced peritonitis, LPS-induced sepsis, breast cancer, glioblastoma, and Alzheimer's disease .
    ODZ10117
  • HY-182323
    SGK1-IN-7

    		SGK Tau Protein Neurological Disease
    SGK1-IN-7 is a blood-brain barrier-permeable SGK1 inhibitor with an IC50 of 0.72 μM. SGK1-IN-7 reduces the phosphorylation level of TAU protein at the Ser396 and Ser214 epitopes. SGK1-IN-7 antagonizes the toxicity induced by Okadaic acid (HY-N6785). SGK1-IN-7 can be used in the research of Alzheimer's disease .
    SGK1-IN-7
  • HY-N16831
    Moracenin D

    		Drug Derivative Others
    Moracenin D is a natural flavonoid.
    Moracenin D
  • HY-D3250
    PYSNO

    		Fluorescent Dye NO Synthase Cardiovascular Disease
    PYSNO is a lysosome-targeted fluorescent probe based on a pyridazinone skeleton (λem=515-565 nm, λex=405 nm) that can be used to track nitric oxide (NO) production in vivo. PYSNO exhibits a rapid, highly sensitive and highly selective "turn-on" response to endogenous and exogenous NO by blocking photoinduced electron transfer and regulating radiative decay rates. PYSNO enables precise in vivo monitoring in a mouse model of myocardial fibrosis and can be applied to the research of related diseases .
    PYSNO
  • HY-183805
    5-HT6R/FAAH modulator 2

    		5-HT Receptor FAAH Neurological Disease
    5-HT6R/FAAH modulator 2 is a dual 5-HT6R antagonist and FAAH inhibitor with human 5-HT6R pKi 7.24, human FAAH pIC50 5.47, and blood-brain barrier penetration.5-HT6R/FAAH modulator 2 modulates serotonergic signaling, blocks 5-HT6R function, inhibits endocannabinoid degradation via FAAH catalytic activity suppression.5-HT6R/FAAH modulator 2 exhibits neuroprotective effects against mitochondrial dysfunction, amyloid-β, and glutamate-induced toxicity, reverses memory deficits.5-HT6R/FAAH modulator 2 shows reduced cytotoxicity relative to oxygen-containing lead compounds.5-HT6R/FAAH modulator 2 can be used for the research of Alzheimer's disease .
    5-HT6R/FAAH modulator 2
  • HY-182328
    BTA-EG6

    		Amyloid-β Neurological Disease
    BTA-EG6 is a brain-penetrant aggregated amyloid-β (Aβ) peptide binder with a Kd of 290 nM for Aβ1-42. BTA-EG6 binds to aggregated Aβ and forms protein-resistive coatings that block interactions between Aβ and catalase. BTA-EG6 protects neuroblastoma cells from Aβ-induced toxicity and oxidative stress, and inhibits Aβ-induced increases in cellular hydrogen peroxide (H2O2) levels. BTA-EG6 can be used for the research of alzheimer’s disease (AD) .
    BTA-EG6
  • HY-183272
    PI3K/Akt/mTOR-IN-7

    		Akt mTOR JAK STAT Apoptosis Caspase Reactive Oxygen Species (ROS) NO Synthase Cardiovascular Disease Neurological Disease
    PI3K/Akt/mTOR-IN-7 is an AKT/mTOR and JAK2/STAT3 inhibitor. PI3K/Akt/mTOR-IN-7 restores p-Akt, p-mTOR, and p-STAT3 expression, reduces pro-apoptotic Caspase-3 mRNA expression. PI3K/Akt/mTOR-IN-7 reduces intracellular ROS accumulation and inhibits NO production. PI3K/Akt/mTOR-IN-7 can be used for research on stroke, Alzheimer's disease and Parkinson's disease .
    PI3K/Akt/mTOR-IN-7
  • HY-P992057
    Armanezumab

    		Tau Protein Neurological Disease
    Armanezumab is a monoclonal antibody that targets and inhibits tau protein, and it specifically binds to the exposed N-terminal domain of pathological tau protein. Armanezumab can be used in relevant studies on Alzheimer's disease, frontotemporal dementia, and Pick's disease .
    Armanezumab
  • HY-181406
    eIF2B activator-1

    		Eukaryotic Initiation Factor (eIF) Potassium Channel Neurological Disease
    eIF2B activator-1 (Compound 7a) is a eIF2B activator with a pEC50 value of 7.3. eIF2B activator-1 exhibits significant hERG inhibitory activity, with a pIC50 value of 5.7. eIF2B activator-1 can be used in research related to Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
    eIF2B activator-1
  • HY-D3224
    HCP

    		Fluorescent Dye Neurological Disease
    HCP is a two-photon fluorescent probe capable of crossing the blood-brain barrier, which is specifically designed for real-time detection of hypochlorous acid (HClO/ClO -) produced by myeloperoxidase (MPO). Chlorination of the quinoline skeleton of HCP generates HCP-Cl, which eliminates intramolecular charge transfer (ICT) quenching and thereby produces fluorescence. HCP is suitable for in vivo dynamic imaging of HClO in the brains of epileptic mice and high-throughput screening of antiepileptic drugs (HCP-Cl: Ex/Em = 800 nm/495 nm) .
    HCP

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: